Maravai LifeSciences Holdings, Inc.(MRVI)Earnings, Financials & Key RatiosMaravai LifeSciences Holdings, Inc. (MRVI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company has significantly improved its debt profile by reducing total liabilities to $344.1 million in 2026Q1, the persistent volatility in operating cash flow and the fragile return to a 3.8% operating margin suggest that the business model has yet to achieve a stable, long-term growth trajectory.
Maravai LifeSciences Holdings, Inc. (MRVI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Maravai LifeSciences Holdings, Inc. (MRVI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.01vs $0.05+120.0% | $66Mvs $53M+24.2% |
| Q1 2026 | Feb 25, 2026 | $0.04vs $0.07+42.9% | $50Mvs $49M+1.7% |
| Q4 2025 | Nov 6, 2025 | $0.08vs $0.06-33.3% | $42Mvs $49M-15.1% |
| Q3 2025 | Aug 11, 2025 | $0.08vs $0.06-33.3% | $47Mvs $50M-5.4% |
Recent stock market news and headlines for Maravai LifeSciences Holdings, Inc. (MRVI)
TriLink, part of Maravai LifeSciences (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to h
JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA therapeutic developers simplify sourcing and scale production more efficiently. The facility supports a coordinated supply of key RNA manufacturing and IVT workflow materials from early research through commercial production. The launch addresses a long-standing pain point for RNA therapeutics develo.
Key metrics vs top competitors for Maravai LifeSciences Holdings, Inc. (MRVI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.90 | $856.06M | -6.48 | -28.34% | -70.41% | -27.53% | — | |
| $25.67 | $1.18B | -21.04 | 3.55% | -29.86% | -10.69% | — | |
| $123.72 | $9.1B | -21.15 | — | — | -42.78% | — | |
| $4.58 | $5.78M | -0.09 | -81.82% | -2530.85% | — | — | |
| $313.04 | $41.77B | 134.35 | 65.19% | 13.46% | 98.29% | — | |
| $194.33 | $29.52B | 35.66 | -0.78% | 19.43% | 32.84% | — |
Maravai LifeSciences Holdings, Inc. (MRVI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Maravai LifeSciences Holdings, Inc. (MRVI) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 7, 2026·SEC
Feb 25, 2026·SEC
Nov 6, 2025·SEC
Get notified when MRVI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Maravai LifeSciences Holdings, Inc. (MRVI) stock FAQ — growth, dividends, profitability & financials explained
Maravai LifeSciences Holdings, Inc. (MRVI) reported $204.7M in revenue for fiscal year 2025. This represents a 65% increase from $123.8M in 2018.
Maravai LifeSciences Holdings, Inc. (MRVI) saw revenue decline by 28.3% over the past year.
Maravai LifeSciences Holdings, Inc. (MRVI) reported a net loss of $104.6M for fiscal year 2025.
Maravai LifeSciences Holdings, Inc. (MRVI) has a return on equity (ROE) of -27.5%. Negative ROE indicates the company is unprofitable.
Maravai LifeSciences Holdings, Inc. (MRVI) had negative free cash flow of $51.9M in fiscal year 2025, likely due to heavy capital investments.
